ABBV at a glance
AbbVie Inc (ABBV, SEC CIK 1551152) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on October 5, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), AbbVie Inc (ABBV) reported revenue of $61.2 billion (up 8.6% from FY2024) and net income of $4.2 billion. Diluted EPS was $2.36.
- As of June 30, 2026, 72 institutional investment managers tracked by SignalX reported holding AbbVie Inc (ABBV) shares worth $172.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Donoghoe Nicholas on August 14, 2026 of 32,710 shares at $250.00 per share.
- In the last 90 days, ABBV insiders reported 0 open-market purchases ($0) and 1 open-market sale ($8.2M) on Form 4, a net sale of $8.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $61.2B
- +8.6% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$8.2M
- 13F holders
- 72 funds
- $172.5B · +0 vs prior quarter
- Latest 8-K
- Sep 3, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: global biopharmaceutical company focused on innovative therapies in immunology, neuroscience, oncology, aesthetics, and eye care
- New emphasis: expanded indications and geographic approvals for Skyrizi and Rinvoq across autoimmune diseases, plus new oncology ADC Epkinly approved for lymphoma
- Strategic shift: single global business segment operating model aligned for unified resource allocation and long-term strategic goal achievement
- Quantitative highlight: 2025 gross revenues in U.S. distributed mostly through three wholesalers, none exceeding 43% share
- Noteworthy fact: continued biosimilar competition pressure on Humira globally, with evolving FDA regulatory pathway and complex approval process
Risk Factors
- FDA approval and EC marketing authorization for Rinvoq in 2025 for giant cell arteritis and ulcerative colitis, supporting U.S. exclusivity through April 2037
- Global minimum tax "Pillar Two" implementation starting 2024 raising future income tax expense uncertainty under OECD rules
- Capital investment including new U.S. API facility in Illinois and biologics expansion in Massachusetts increases operational complexity and execution risk
- Biosimilar competition driving Humira U.S. net revenues down 57% in 2025 threatens market position and revenue stability
- $6.5B contingent consideration liabilities fair value increase in 2025 linked to Skyrizi sales projections creating significant financial risk exposure
Management Discussion & Analysis
- Revenue $61.2B, up 9% YoY on reported and constant currency basis
- Operating earnings $15.1B, operating margin approximately 24.7% (15.1B/61.2B)
- Best segment: not explicitly broken down; costs include $7.4B amortization, $6.5B contingent liabilities fair value change
- Cash flow from operations $19.0B, no disclosed buybacks or dividends, ongoing investment in pipeline and brands
- Forward outlook: $100B pledged for US R&D/capex over decade, tariff exemption for 3 years, risk of revenue erosion from Medicare price controls starting 2026
AI summary of the ABBV 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $16,990M, up 10.2% YoY from $15,423M
- Gross margin 75% vs 72% YoY; effective tax rate 15% vs 39%
- Best performer: Skyrizi revenue $5,505M, up 24.4% YoY
- Worst performer: Humira revenue $756M, down 35.9% YoY
- Operating cash flow $7,265M vs $6,788M; dividends $6.2B and buybacks $1.1B in six months
AI summary of the ABBV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Forward-looking disclosure covers 2026 full-year and third-quarter adjusted diluted EPS guidance
- Apogee acquisition benefits and integration expected to influence adjusted diluted EPS
Item EX-99.1: Item EX-99.1
- Apogee acquisition completed for $135.11 per share in cash, valuing equity at approximately $10.9 billion
- Pipeline adds late-stage zumilokibart for atopic dermatitis and APG273 for asthma, strengthening AbbVie’s immunology growth strategy
Item 8.01: Other Events
- $10.0B senior notes issued on August 18, 2026, spanning maturities from 2028 to 2066
- Fixed-rate coupons range from 4.500% to 6.100%; floating-rate notes mature in 2028
AI summaries of ABBV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ABBV
Don't miss the next ABBV filing
- Alerts as it files. A push when ABBV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ABBV, by share count.
- Ask anything. An AI agent that reads every ABBV filing and answers with sources.
ABBV alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| RAPP EDWARD J | A | Sep 30, 2026 | 129 | $261.59 |
| Quaggin Susan E | A | Sep 30, 2026 | 59 | $261.59 |
| Donoghoe Nicholas | M | Aug 14, 2026 | 32,710 | $79.02 |
| Donoghoe Nicholas | M | Aug 14, 2026 | 32,710 | - |
| Donoghoe Nicholas | Sell | Aug 14, 2026 | 32,710 | $250.00 |
| Quaggin Susan E | A | Jun 30, 2026 | 62 | $251.64 |
| FALK THOMAS J | A | May 8, 2026 | 1,118 | - |
| AUSTIN ROXANNE S | A | May 8, 2026 | 1,118 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $56.3B | $61.2B |
| Gross Profit | - | $10.7B | $12.1B |
| Operating Income | - | $9.1B | $15.1B |
| Net Income | - | $4.3B | $4.2B |
| Gross Margin | - | 19.0% | 19.7% |
| Op. Margin | - | 16.2% | 24.6% |
| Net Margin | - | 7.6% | 6.9% |
| Balance Sheet | |||
| Total Assets | $134.7B | $135.2B | $134.0B |
| Equity | $10.4B | $3.3B | -$3.3B |
| ROE | - | 128.7% | -129.2% |
| Per Share | |||
| EPS | - | $2.39 | $2.36 |
| Cash Flow | |||
| Operating CF | - | $18.8B | $19.0B |
| CapEx | - | $974.0M | $1.2B |
Source: XBRL data in AbbVie Inc (ABBV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ABBV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 72 | $172.53B |
| Q1 2026 | 72 | $148.35B |
| Q4 2025 | 70 | $157.03B |
| Q3 2025 | 75 | $176.69B |
| Q2 2025 | 72 | $130.89B |
| Q1 2025 | 68 | $114.48B |
| Q4 2024 | 64 | $70.24B |
| Q3 2024 | 58 | $39.23B |
- Franklin Resources+5.37M (+37%)
- Citadel Advisors LLC+2.68M (+547%)
- T. Rowe Price Group+1.75M (+13%)
- D.E. Shaw & Co+1.43M (+212%)
- State Street Corp+1.38M (+2%)
- JPMorgan Chase & Co−8.88M (-16%)
- Bank of America Corp−2.70M (-11%)
- BlackRock−1.21M (-1%)
- Vanguard Portfolio Management LLC−1.05M (-2%)
- FMR LLC (Fidelity)−988.9K (-5%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 551 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ABBV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 5, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 3, 2026 | - | Analysis | - |
| 8-K | Aug 18, 2026 | - | Analysis | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 31, 2026 | - | Analysis | - |
| 8-K | Jul 6, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 8-K | May 12, 2026 | - | Analysis | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 10-Q | May 8, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
- ACET · Adicet Bio IncPharmaceutical Preparations
ABBV SEC filings: frequently asked questions
Are ABBV insiders buying or selling?
In the last 90 days, AbbVie Inc (ABBV) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $8.2 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ABBV stock?
As of June 30, 2026, the largest AbbVie Inc (ABBV) holders among the 13F filers tracked by SignalX were BlackRock ($37.6 billion), Vanguard Capital Management LLC ($29.0 billion), State Street Corp ($20.8 billion), Vanguard Portfolio Management LLC ($12.2 billion), JPMorgan Chase & Co ($12.2 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ABBV's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), AbbVie Inc (ABBV) reported revenue of $61.2 billion (up 8.6% from FY2024) and net income of $4.2 billion. Diluted EPS was $2.36. The figures come from the XBRL data in the 10-K.
What are the main risks in ABBV's latest 10-K?
In the 10-K filed February 20, 2026, AbbVie Inc (ABBV) flagged: FDA approval and EC marketing authorization for Rinvoq in 2025 for giant cell arteritis and ulcerative colitis, supporting U.S. exclusivity through April 2037. Global minimum tax "Pillar Two" implementation starting 2024 raising future income tax expense uncertainty under OECD rules. (AI summary of the Risk Factors section.)
What did ABBV report in its latest 8-K?
AbbVie Inc (ABBV) filed an 8-K on September 3, 2026 reporting Item 7.01 (Regulation FD Disclosure). Forward-looking disclosure covers 2026 full-year and third-quarter adjusted diluted EPS guidance.
What are the latest ABBV SEC filings?
AbbVie Inc (ABBV) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on October 5, 2026 and a Form 4 insider filing on October 2, 2026.
What is ABBV's SEC CIK number?
AbbVie Inc (ABBV)'s SEC Central Index Key (CIK) is 1551152. EDGAR lists every ABBV filing under that number.
Ask anything about ABBV
The research agent reads ABBV's filings, financials, insider trades and 13F holders, then answers with sources.